Candriam SCA’s Epizyme, Inc EPZM Stock Holding History

Candriam SCA’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-66,329	Closed	-$340K	–	888
2021 Q3	$340K	Hold	66,329	–	–	﹤0.01%	803
2021 Q2	$551K	Sell	66,329 -39,561	-37%	-$334K	﹤0.01%	791
2021 Q1	$1.1M	Hold	105,890	–	–	0.01%	619
2020 Q4	$1.15M	Sell	105,890 -255,262	-71%	-$3.15M	0.01%	631
2020 Q3	$4.31M	Buy	361,152 +96,138	+36%	+$1.29M	0.04%	375
2020 Q2	$4.26M	Buy	265,014 +47,638	+22%	+$832K	0.04%	366
2020 Q1	$5.23M	Buy	217,376 +38	+0%	+$816	0.06%	334
2019 Q4	$5.35M	Buy	217,338 +105,838	+95%	+$1.57M	0.06%	341
2019 Q3	$1.15M	Buy	+111,500	New	+$1.41M	0.02%	585
2017 Q2	–	Sell	-192,000	Closed	-$3.29M	–	723
2017 Q1	$3.29M	Sell	192,000 -17,000	-8%	-$226K	0.06%	349
2016 Q4	$2.53M	Buy	209,000 +25,000	+14%	+$261K	0.06%	323
2016 Q3	$1.81M	Hold	184,000	–	–	0.04%	375
2016 Q2	$1.88M	Buy	184,000 +24,000	+15%	+$268K	0.05%	324
2016 Q1	$1.93M	Sell	160,000 -21,000	-12%	-$212K	0.05%	329
2015 Q4	$2.9M	Buy	181,000 +25,000	+16%	+$371K	0.08%	254
2015 Q3	$2.01M	Sell	156,000 -6,000	-4%	-$121K	0.05%	341
2015 Q2	$3.89M	Buy	162,000 +32,000	+25%	+$616K	0.08%	276
2015 Q1	$2.44M	Buy	130,000 +60,000	+86%	+$1.24M	0.05%	361
2014 Q4	$1.32M	Buy	+70,000	New	+$1.64M	0.03%	413

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Candriam SCA's EPZM Position: Q4 2021 in Review

Candriam SCA sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 66,329 shares — an estimated $340K sold.

Candriam SCA first reported a position in EPZM in Q4 2014 and held it in 19 quarters. The position peaked at $5.35M in Q4 2019. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

Candriam SCA reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
Candriam SCA sold 66,329 Epizyme, Inc shares in Q4 2021, an estimated $340K.
Candriam SCA first reported a position in Epizyme, Inc in Q4 2014 and held it in 19 quarters.
Candriam SCA's Epizyme, Inc position peaked at $5.35M in Q4 2019.
132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.